StockData
RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF

Radiopharm Theranostics Ltd

Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Sep 30, 2026
$0.96−0.07 (-6.50%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

About Radiopharm Theranostics

Pharmaceutical Preparations, SIC 2834

The provided text does not contain factual descriptions of the company's business activities, main commercial products, business segments, or customer base. The text consists almost entirely of XBRL metadata tags, accounting line tags, and a brief note regarding accrued receivables from the Australian Taxation Office. Consequently, specific information about operational segments, offerings, and customers is absent from the provided source.

Furthermore, the text provides no information regarding the company's operational scale, physical footprint, operating facilities, or headquarters location. It only lists accounting identifiers, dates, and related entities or intellectual property tags without detailing where the company operates or where its corporate headquarters are located.

Summary of the business section of Radiopharm Theranostics's latest annual report, written by StockData.

Company profile

Company

Legal name
Radiopharm Theranostics Ltd
Headquarters
Carlton Vic, Australia
Address
Level 3, 62 Lygon Street 3053
Phone
61 3 9824 5254
Employees
2, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
C3
Fiscal year ends
June 30
Auditor
GRANT THORNTON AUDIT PTY LTD, Melbourne, Australia

Stock & identifiers

Ticker
RADX
Other tickers
RDPTF
Exchange
Nasdaq
Shares outstanding
3.54B, Jun 30, 2026
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
1949257
CUSIP
75041J101
ISIN
US75041J1016
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Riccardo CanevariManaging Director and CEO22,679,986
Dimitris VoliotisChief Medical Officer–
Aaron James LauritaChief Financial Officer26,357
Paul HopperDirector147,721,428
Ian Lawrence TurnerDirector9,985,292
Noel DonnellyDirector–
Hester Denise LarkinDirector644,247
Bruce Michael GoodwinDirector–

Employees

Headcount reported in annual reports

“June 30, 2026, 1 employee was employed in the United Kingdom, 2 employees were employed in Australia and 11 employees were employed in”